WELCOME
WELCOME BACK HERE EVERYONE. COULD AN ARTHRITIS DRUG BE A POSSIBLE
TREATMENT FOR KOVIC? NINETEEN
SPECIFICALLY WHEN PATIENTS
EXPERIENCE PNEUMONIA UC SAN
DIEGO HEALTH HAS LAUNCHED A
PHASE 3 CLINICAL TRIAL. AND
JOINING US NOW IS DR. OUT TUOL
MALHOTRA, PROFESSOR OF
RESPIRATORY MEDICINE TO SHARE
THE IMPORTANCE OF THESE TRIALS.
GOOD MORNING TO YOU, DOCTOR.
THANKS FOR BEING HERE. GOOD
MORNING. GIVE US THE NAME OF
THIS TREATMENT. WHAT
THE OUTCOME IS THAT WE'RE ALL
HOPING FOR AND IF THIS DRUG IS
IN FACT A VIABLE TREATMENT AT
THIS POINT THERE IS A DRUG
CALLED COUNSELORS A MAP WHICH
WE'RE NOW STUDYING TO DRUG
THAT'S BEEN AROUND FOR WHILE
BEING USED TO TREAT ARTHRITIS
AND SOMETHING CALLED CYTOKINE
STORM CYTOKINE RELEASE
SYNDROME. AND WE BELIEVE IT MAY
HAVE SOME VALUE COVERED
PNEUMONIA AS WELL. SO WE'RE
TRYING TO ENROLL ABOUT 450
PATIENTS AROUND THE WORLD AND
WE'RE ABOUT HALFWAY THROUGH
THE STUDY NOW. SO PHASE 3 WHERE
YOU'VE BEEN ABOUT HALFWAY
THROUGH THE PROCESS, WHEN WILL
WE. RIGHT. OH, IF IT CAN REDUCE
THE INFLAMMATION IN THE LUNGS
BECAUSE THAT'S THE GOAL HERE,
RIGHT? WELL, THERE ARE TWO
GOALS. ONE IS TO REDUCE
INFLAMMATION FOR SURE. BUT
PERHAPS THE BIGGER GOAL IS TO
REDUCE THE SUFFERING PATIENTS.
SO WE'RE LOOKING FOR
IMPROVEMENTS IN CLINICAL
OUTCOMES THAT PATIENTS DON'T
NEED RESPIRATORS AS MUCH AND
ARE NOT REQUIRING AS MUCH
OXYGEN. SO WE'RE LOOKING FOR
CLINICAL IMPROVEMENTS IN THEIR
CARE AND HOPEFULLY THEY'LL DO
BETTER AS A RESULT OF THIS
TREATMENT. I WAS READING SOME
PROMISING RESULTS OF THIS DRUG
ON PATIENTS IN CHINA. CAN YOU
TELL US ABOUT THAT? THAT'S A
RATHER SMALL STUDY BUT IT'S
SOME PROMISING RESULTS. YOU
KNOW, THERE'S BEEN A FEW
STUDIES ON TURTLE ISM WHICH
HAVE BEEN DONE IN ITALY AS WELL
AS IN CHINA. SOME DATA CAME OUT
IN EUROPE LAST WEEK OR ACTUALLY
JUST A FEW DAYS AGO. NOW ABOUT
200 PATIENTS IN A RANDOMISED
TRIAL WHERE THEY DID SHOW SOME
IMPROVEMENTS IN THE NEED FOR
EITHER MECHANICAL VENTILATION
OR DEATH. IT WAS A SMALL
STUDIES ABOUT 200 PATIENTS BUT
IT WAS PROMISING AND WE'RE
PUSHING ON WITH THIS STUDY.
IT'S PREMATURE TO DRAW
CONCLUSIONS. SO WE'RE VERY MUCH
FOCUSED ON COMPLETING THIS
STUDY. BUT SO FAR SO GOOD. WE
HAVE WHAT'S CALLED EQUIPOISE
WHERE WE DON'T KNOW WHICH
TREATMENT IS BETTER. AND SO
WE'RE PUSHING ON TO TRY AND
COMPLETE THE STUDY THAT'S
ONGOING. HOW DOES TOTAL VISIT
MAB DIFFER FROM
THE HYDROCHLORIC WHEN WE'VE
HEARD SO MUCH ABOUT TO
SOCIALISM AB A BLOCK SOMETHING
CALLED AISLE SIX AISLE SIX ONE
OF THE PROTEINS IN THE BLOOD
THAT IS RELATED TO INFLAMMATION
AND THERE'S AN AISLE SIX
RECEPTOR THAT THIS DRUG IS
SPECIFICALLY TARGETING
HYDROXIDE CHLOROQUINE IS A DRUG
THAT'S USED FOR MALARIA AND
RHEUMATOID ARTHRITIS WHETHER
IT'S EFFECTIVE FOR COVERED WE
DON'T KNOW. SO FAR THE DATA DO
NOT LOOK VERY PROMISING BUT
THERE'S OVER 90 ONGOING STUDIES
ON HOW DRUGS AND CHLOROQUINE.
SO MAYBE TIME WILL TELL. WE
TALK ABOUT THESE CLINICAL
TRIALS THE PHASE 3S AND ALL
THESE THINGS. BUT TO OUR
VIEWERS AT HOME, WHY ARE THESE
TRIALS THE PROCESS HERE SO
IMPORTANT? WELL, SO IF WE JUST
GIVE DRUGS HAPHAZARDLY, IF WE
JUST SAY WELL, I THINK THIS
MIGHT WORK OR THAT MIGHT WORK,
WE'LL NEVER LEARN THE TRUTH. WE
DON'T KNOW WHAT WORKS, WHAT
DOESN'T. MANY OF THE PATIENTS
IN NEW YORK AND ON THE EAST
COAST ARE GETTING LOTS THESE
THERAPIES SORT OF EMPIRICALLY
MEANING WE DON'T KNOW IF
THEY'RE WORKING OR NOT BUT
WE'LL NEVER REALLY LEARN
THE TRUTH. AND SO THAT'S ONE
ISSUE. SECOND ISSUE IS THESE
DRUGS HAVE SIDE EFFECTS AND SO
LIKE EVERY TREATMENT IN
MEDICINE, THIS RISK AND BENEFIT
IF YOU JUST GONNA GIVE THINGS
NILLY YOU'LL YOU'LL NEVER QUITE
KNOW WHAT'S WORKING. AND THEN
THE THIRD ISSUE IS WE DEPLETE
THE STORIES THESE DRUGS. SO FOR
EXAMPLE, CHLOROQUINE AND
HYDROXIDE CHLOROQUINE ARE USED
TO TREAT RHEUMATOID ARTHRITIS
AND LUPUS AND DIFFERENT KINDS
OF MALARIA ILLNESSES AROUND
THE WORLD. MALARIA KILLS OVER
HALF A MILLION PEOPLE PER YEAR.
AND IF WE LOSE THOSE DRUGS FOR
OUR PATIENTS, THERE'LL BE A
RISK FOR THOSE PATIENTS AS
WELL. THAT IS TO SAY DEPLETING
THAT DRUG STORE IS GOING TO
HAVE CONSEQUENCES. WE DON'T
EVEN KNOW IF IT WORKS OR NOT
UNCOVERED. YOU'VE BEEN STUDYING
THIS. YOU'RE AT THE FOREFRONT
OF THE MEDICAL COMMUNITY HERE.
HOW FAR AWAY DO YOU THINK WE
ARE TO A VACCINE FOR KOBE 19 AT
THIS POINT? SO DISCUSSION IS
DONE BY THE END OF THIS
CALENDAR YEAR THERE'LL BE A
VACCINE I BELIEVE PFIZER'S
LAUNCHED A VACCINE TRIAL IN
THE EARLY STAGES WHICH WHICH IS
GOOD NEWS. THERE'S SOME GOOD
NEWS YESTERDAY ABOUT REM DESERT
AREA ALSO UCSD WAS
PARTICIPATING THAT DAN SWEENEY
AND CONNIE BENTZ AND OTHERS AND
DIEGO PART OF OUR TEAM THAT ARE
VERY MUCH PUSHING FORWARD WITH
DIFFERENT DRUG THERAPIES. SO
THERE'S SOME PROMISING NEWS AND
SOME LIGHT AT THE END OF
THE TUNNEL. DOCTOR, REALLY
APPRECIATE YOUR TIME HERE THIS
MORNING. AND A LITTLE BIRDIE
TOLD ME IT'S YOUR DAUGHTER'S
BIRTHDAY TODAY. HAPPY BIRTHDAY.
BIG 6 SWEET 16 FOR HER. I
UNDERSTAND SIX STUDENTS IS ON
LOCKDOWN FOR A BIRTHDAY A SHOW
OF FUN. YEAH, MY TWO KIDS WILL
BE TWO BUT WE